BioNxt Solutions updates sublingual Cladribine program for MS, plans human study in 2025.

BioNxt Solutions Inc. updated its sublingual Cladribine program for Multiple Sclerosis (MS), designed to assist patients with swallowing difficulties. Positive results from animal studies were reported, and a human comparative bioequivalence study is planned for early 2025. The company received a favorable patent examination for sublingual delivery of anticancer drugs targeting autoimmune neurodegenerative diseases and aims to expand its patent portfolio. BioNxt is also developing a delivery system for Myasthenia Gravis.

September 26, 2024
9 Articles